Purpose To evaluate adherence to European Society of Endocrinology guidelines and risk of renal complications in patients with chronic post-operative hypoparathyroidism (PO-HypoPT) treated with calcium and activated vitamin D metabolites. Methods We evaluated 90 adult patients (68 females and 22 males) with chronic (3 years) PO-HypoPT. Total albumincorrected (Alb-Ca) and ionized serum calcium, phosphate, creatinine, PTH, and 24-h urinary calcium were measured; renal ultrasound was also performed. Healthy hospital employers (n = 142) were used as control. Results Complete data were available in 82 patients. Twenty-eight (34.1%) met four targets (Alb-Ca, phosphate, calcium phosphate product and 24-h urinary calcium), 36 (43.9%) three, 17 (20.7%) two, and 1 (1.2%) one. Thirteen (14.4%) had Alb-Ca value below and 18 (20.0%) above the target range and 54.9% 24-h urinary calcium above the upper normal limit. Seven (7.7%) has increased serum phosphate and none an increased calcium phosphate product. Eleven (12.2%) patients had eGFR < 60 mL/min × 1.73 m 2 . Nephrolithiasis was present in 27 (30%) patients. Compared with the controls, patients had lower Alb-Ca (8.9 ± 0.5 vs. 9.5 ± 0.3 mg/dL, P 0.0001) and a higher rate of kidney stones, mostly asymptomatic [27/90 (30%) vs 7/142 (5%), P < 0.0001, odd ratio 8.2 (3.4-19.9)]. Fifty-seven patients had ≥ four serum Ca 2+ determinations during follow-up. Forty (70.2) patients had values within the target range in > 50% of cases, 18 in > 75%, and only 2 in 100%. Two patients never had values in the target range. Conclusions Treatment of chronic PO-HypoPT with calcium and activated vitamin D metabolites is suboptimal and associated with an increased risk of renal complications.
Introduction
Hypoparathyroidism (HypoPT) is a rare endocrine disorder characterized by reduced levels of serum calcium, increased levels of serum phosphorus and undetectable or inappropriately low serum parathyroid hormone (PTH) [1] . HypoPTH most commonly follows neck surgery, particularly thyroid surgery [2, 3] . Epidemiological data indicate that post-operative hypoparathyroidism (PO-HypoPT) is the most frequent complication of aggressive thyroid surgery [4] . PO-HypoPT can be transient, or permanent. Transient PO-HyPT is relatively common and is due to reversible parathyroid stunning; it usually resolves within few weeks, but in some cases it may last longer [5] . Chronic PO-HypoPT is caused by an irreversible parathyroid damage (ischemia, electric scalpel damage and, rarely, accidental or inevitable removal of a parathyroid gland) and persists for at least 6 months after surgery.
Until recently, HypoPT was the only major endocrine disorder in which the hormonal failure was not treated with the native hormone, PTH. Early in 2015, the Food and Drug Administration in North America has approved the use of recombinant human full-length PTH (rhPTH ) for the management of chronic HypoPT for "patients not well controlled on conventional treatment, namely oral calcium and active forms of vitamin D" [6, 7] . rhPTH is currently available in few countries and, therefore, most patients are treated with conventional therapy based on the use of calcium and/or activated vitamin D and, exceptionally, high A. Meola and E. Vignali contributed equally to the study. doses of native vitamin D. This treatment is aimed to correct hypocalcemia and related symptoms while serum calcium is maintained in the low-normal range or slightly, but most patients do not recover a complete well-being. Moreover, conventional treatment does not fully restore calcium homeostasis, because of the lack of direct (kidney and bone) or indirect (intestine) actions of PTH on target tissues and is associated with insidious complications that may be silent for decades. As a matter of fact, two recent large cohort studies of patients with chronic HypoPT have shown an increased risk of renal comorbidities, neuropsychiatric complications, infections, and seizures [8, 9] . Guidelines for the management of chronic HypoPT have only recently developed by the European Society of Endocrinology (ESE) and a panel of international experts.
The ESE guidelines suggest that the goal of treatment is "to relieve hypocalcemic symptoms while serum calcium is maintained in the low-normal range or slightly below" [6] . No data exist to indicate the optimal individual serum calcium levels during treatment of HypoPT.
The present study was designed to prospectively evaluate the adequacy of conventional therapy according to the ESE guidelines and the rate of renal complications in a cohort of patients with chronic PO-HypoPT followed at a tertiary endocrine referral center.
Materials and methods

Patients
Consecutive patients with chronic PO-HypoPT scheduled for visit at the outpatient clinic of Endocrine Unit of the University Hospital of Pisa between 1 June 2015 and 31 May 2016 were identified. Patients with a diagnosis of chronic PO-HypoPT since at least 3 years were eligible for the study. Exclusion criteria were a history of chronic kidney disease, kidney tumors, symptomatic nephrolithiasis prior to thyroid surgery, the diagnosis of primary hyperparathyroidism before thyroid surgery and evidence of bone metastases. One hundred patients who met the study criteria were contacted by telephone and/or e-mail and 90 accepted to participate to the study.
The study protocol included measurement of fasting serum albumin-corrected total calcium (Alb-sCa), ionized calcium, albumin, phosphate, creatinine, 25-hydroxyvitamin d (25OHD) and 24-h urine calcium. Renal ultrasound was also performed.
One hundred forty-two healthy Hospital employers, matched for sex and age, undergoing routine medical evaluation, which included serum Alb-Ca, creatinine and abdomen ultrasound, were used as control.
All patients were followed in our outpatient clinic since the first follow-up visit after thyroidectomy, and were seen every 12-18 months for the follow-up of thyroid cancer.
The Internal Review Board approved the study and informed consent was obtained from all participants.
Methods
Serum calcium, albumin, creatinine, phosphate, and urinary calcium were measured using standard methods. Estimated glomerular filtration rate was calculated using the CKD-EPI equation [10] .
Statistical analyses
Normality was evaluated using the Kolmogorov-Smirnov test. Results are expressed as mean ± standard deviation unless not-normally distributed, in which case median and interquartile ranges (IR) are reported. Differences between continuous variables were assessed using two-tailed t test. Categorical variables were compared using the χ 2 or Fisher's exact test, as appropriate.
Statistical analysis was performed using the program SPSS, v. 20. P values < 0.05 were considered statistically significant.
Results
Baseline demographic and biochemical data are reported in Table 1 .
The study cohort consisted of 90 adult patients (68 females and 22 males with a mean age of 50 ± 14 and 57 ± 14, respectively) with chronic PO-HypoPT following total thyroidectomy for: (92.2%) had a diagnosis of differentiated thyroid cancer (n = 83, 92.2%), nontoxic goiter (n = 5, 5.5%), and Graves' disease (2, 2.2%). The median average follow-up after surgery at the time of current evaluation was 7.0 (range 3-36 years, IQR 4-11). Patients with thyroid cancer were also submitted to ablation of the thyroid residue with radioiodine. At the time of evaluation, all patients were treated with calcitriol (median 1 μg/die; range 0.25-2, IQR 0.5-1), 35 were given additional treatment with calcium as carbonate (median 1000 mg/die; range 500-4000, IQR 500-1000) and 2 thiazide diuretics. All patients were euthyroid under levothyroxine therapy. A few patients reported hypocalcemia-related symptoms (n = 10) and comorbidities (n = 21).
For the purpose of subsequent analyses, targets defined by the recent ESE guidelines were used and results are depicted in Fig. 1 . The mean level of Alb-Ca was 8.9 ± 0.5 mg/dL (range 7.5-10.1), and values that did 1 3 not meet the ESE target range were found in 31 (34.4%) patients. In particular, 13 (14.4%) had values below and 18 (20.0%) above the recommended Alb-Ca concentrations. The mean level of serum phosphate was 3.6 ± 0.7 mg/dL (2.2-5.9), and seven (7.7%) patients had values above the upper normal limit. The serum calcium phosphate product was normal (< 55 mg/dL 2 ) in all patients. The mean serum creatinine level was 0.9 ± 0.2 mg/dL (0.6-2.1), and 22 (24.4%) patients had values above the upper normal limit. Mean eGFR was 82 ± 20 mL/min per 1.73 m 2 (33-148), and 11 (12.2%) patients had values < 60 mL/ min per 1.73 m 2 , and none below 30. Serum 25OHD levels were measured in 87/90 patients. The mean value was 31.9 ± 10.3 ng/mL (range 11.7-57.7). Eight patients had values < 10 ng/mL, 36 between 20 and 30 ng/mL, and 43 > 30 ng/mL. Twenty-four hour urinary calcium data were available in 82 patients (data were not available in six cases and the two patients taking thiazide diuretics were excluded), with a mean value of 359 ± 178 mg in males and 290 ± 155 in females. Forty-five [54.9% of the total cohort; 33/63 (52.4%) females and 12/19 (63.2%) males] patients showed values above the upper normal limit (≥ 300 mg in men and ≥ 250 mg in females). There was a slightly statistical significant correlation (P = 0.044) in the whole group between 24-h urinary calcium and AlbsCa, but not with the duration of HypoPT, eGFR, vitamin D status and renal stones. Figure 1 shows the number of patients who were at target for one of more of the following ESE guidelines parameters: serum Alb-Ca, serum phosphate, calcium phosphate product and 24-h urinary calcium. Only 28/82 (34.1%) met the four targets.
Ultrasound revealed the presence of nephrolithiasis, mostly asymptomatic, in 27 (30%) patients with no difference between males and females, but not nephrocalcinosis. There was no correlation (P = 0.976) between the presence of kidney stones and duration of HypoPT, 24-h urinary calcium excretion, Alb-Ca and vitamin D status. 
Comparison of HypoPT patients and controls
Compared with the control group, patients had significantly lower Alb-Ca (8.9 ± 0.5 vs. 9.5 ± 0.3 mg/dL, P = 0.0001) and higher serum creatinine (0.90 ± 0.2 vs 0.91 ± 0.1 mg/dL, P = 0.0008) levels, but no difference in the eGFR. The rate of kidney stones was significantly higher [27/90 (30%) vs 7/142 (5%), P < 0.0001, Odd ratio 8.2 (3.4-19.9)] in patients than in controls.
Retrospective analysis
Measurement of pH-adjusted ionized calcium (Ca 2+ ) was used during follow-up. By assuming that there was a relationship between the lower and upper normal limits of Ca 2+ and the corresponding values of Alb-sCa, we calculated that the former accounts for the 51.8% of the latter. Thus, the target range of Ca 2+ corresponding to that of Alb-Ca (2.1-2.3 mmol/L) recommended by the ESE guidelines was 1.09-1.19 mmol/L (Fig. 2) .
Information on serum Ca 2+ concentration during followup was available in all patients. A total of 505 measurements were available and values within, above or below the previously defined recommended target range were found in 296 (58.6%), 88 (17.4%), and 121 (24.0%) determinations, respectively. Nine (1.8%) values were above the upper normal limit. Fifty-seven patients had four or more serum Ca 2+ determinations (median 7, IQR 5-10). The median Ca 2+ concentration was 1.14 mmol (IQR 1.09-1.18). Forty patients (70.2%) had values within the target range in at least 50% of cases, 18 in more than 75%, and only 2 in 100%. Two patients never had values in the target range. Most of the Ca 2+ determination outside the target range was below the lower limit.
Discussion
In recent years, increased attention has been paid to the management of patients with chronic HypoPT and it has become evident that patients treated with conventional therapy have an increased risk of renal complications (nephrolithiasis, nephrocalcinosis and renal failure) [8, 9] .
The recent development of guidelines for the management of chronic HypoPT prompted us to evaluate the adequacy of treatment according to the targets indicted by the ESE guidelines and the rate of renal complications in a cohort of 90 patients with chronic post-surgical PO-HypoPT.
Our cross-sectional study indicates that, despite being followed at a tertiary endocrine referral center, only 34.1% treated with conventional therapy (calcium and calcitriol) met the biochemical targets defined by the ESE guidelines. The remaining patients were not at target for calcium concentration (34.4%), 24-h urinary calcium (43.9%), and, less frequently, serum phosphate (7.7%). Impaired renal function was present in 22% of patients, and 11 (12.2%) patients had an eGFR < 60 mL/min per 1.73 m 2 . Similar rates of biochemical abnormalities have previously been reported in a few cross-sectional studies that enrolled patients with chronic HypoPT treated with conventional therapy. We found that nephrolithiasis was present in 30% of our patients, a figure higher than that reported by Arlt et al. [ [8] . The lack of correlation between nephrolithiasis and 24-h urinary calcium in our cohort suggest that other parameters may contribute to the precipitations of calcium salt in the urinary tract.
The rate of nephrolithiasis in our patients was significantly (P < 0.0001) higher than that observed in a control group (7%) (OR 8.2; CI 3.4-19.9), where the prevalence was similar to that observed in the normal adult Italian population [13] . rhPTH 1-84 will be available in most countries over next year. The existing experience indicates that this treatment is effective in maintaining serum calcium and phosphate in the appropriate range over 6 years, with a significant decrease of urinary calcium at several time points [14] . Renal function remained stable. The high cost of this treatment will hamper its general use and its prescription will be restricted according to the indication of the regulatory authorities in different countries. Therefore, treatment of chronic HypoPT in the most patients will still rely on the use of conventional therapy.
Our study has limitations: single blood and urine samples were evaluated and assays were performed in singlicate; no complete information was available on the management with calcium and activated vitamin D over the entire follow-up after thyroid surgery.
In conclusion, treatment of chronic PO-HypoPT with calcium and activated vitamin D metabolites is suboptimal and associated with an increased risk of renal complications. In this regard, the recent guidelines particularly emphasize to optimize serum calcium levels and monitor urinary calcium and renal function. The question of whether this improved quality of care will decrease the risk of renal complications remains to be established.
